A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  • STATUS
    Recruiting
  • End date
    Jul 21, 2021
  • participants needed
    3100
  • sponsor
    Bond Avillion 2 Development LP
Send
Updated on 3 December 2020
See if I qualify
corticosteroids
budesonide
forced expiratory volume
albuterol
spirometry
leukotriene receptor antagonist
theophylline
peak expiratory flow
muscarinic antagonists

Summary

This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.

Details
Treatment Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
Clinical Study IdentifierNCT03769090
SponsorBond Avillion 2 Development LP
Last Modified on3 December 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 4 yrs?
Gender: Male or Female
Do you have any of these conditions: Asthma or Asthma (Pediatric) or Allergies & Asthma?
Do you have any of these conditions: Allergies & Asthma or bronchial asthma or Asthma or Asthma (Pediatric) or asthmatic?
Do you have any of these conditions: Asthma or asthmatic or bronchial asthma or Allergies & Asthma or Asthma (Pediatric)?
Do you have any of these conditions: Allergies & Asthma or bronchial asthma or Asthma (Pediatric) or asthmatic or Asthma?
Female or male aged 4 years at the time of informed consent
Physician diagnosis of asthma documented for at least 1 year
Receiving 1 of the following scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1
Medium-to-high-dose inhaled corticosteroid (ICS)
Medium-to-high-dose ICS and 1 additional maintenance therapy from the following: leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or theophylline
Low-to-high-dose ICS in combination with long-acting 2-adrenoreceptor agonist (LABA) with or without one additional maintenance therapy from the following: LTRA, LAMA, or theophylline
Prebronchodilator forced expiratory volume in 1 second (FEV1) of 40 to <90% predicted normal value for adults and adolescents, and 60 to <100% predicted normal value for subjects aged 4 to 11 years after withholding specified medications including short/rapid-acting 2-adrenoreceptor agonist (SABA)
Demonstrate reversibility at Visit 1, with an increase in FEV1 12% (and 200 mL for subjects aged 18 years) relative to baseline after administration of sponsor provided Ventolin via central spirometry. One re-test for reversibility testing is allowed within the screening period in advance of Visit 2
Demonstrate acceptable spirometry performance (i.e., meet American Thoracic Society/European Respiratory Society acceptability/repeatability criteria)
A documented history of at least 1 severe asthma exacerbation within 12 months before Visit 1
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator

Exclusion Criteria

Chronic obstructive pulmonary disease or other significant lung disease (e.g., chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)
Oral corticosteroid/SCS use (any dose and any indication) within 6 weeks before Visit 1
Chronic use of oral corticosteroids (OCS, 3 weeks use in 3 months prior to Visit 1)
Having received any marketed (e.g., omalizumab, mepolizumab, reslizumab, benralizumab) or investigational biologic within 3 months or any other prohibited medication
Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months before Visit 1 (including all forms of tobacco, e-cigarettes [vaping], and marijuana)
Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within 5 years of Visit 1
Historical or current evidence of a clinically significant disease
Cancer not in complete remission for at least 5 years
Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1
History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting informed consent validity
Significant abuse of alcohol or drugs
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name
Edit Delete

Annotated by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet